For that cause, they proposed NK cell treatment combined with a tumor-targeting antibody that induces immunogenic response via the patient’s innate immune system, in order to enhance the intervention against BC and HER2-expressing tumors. The gene discussed is ERBB2; the disease is breast cancer.